Steve Kanes, MD, PhD


Steve Kanes
Steve Kanes, MD, PhD
CEO, EmbarkNeuro

Steve is the Chief Executive Officer at EmbarkNeuro. Steve is a Neuropsychiatrist with a career in basic neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. Prior to joining Ancora he was Chief Medical Officer of Sage Therapeutics, where he led the successful clinical development of ZULRESSO® (brexanolone), the first-ever treatment approved for Postpartum Depression (PPD), along with the buildout of the development organization and Sage Therapeutics’ broad neuroscience portfolio. Earlier in his career, Steve was Executive Director in Clinical Development in the Inflammation, Neuroscience and Respiratory therapeutic areas at AstraZeneca, and a faculty member of the University of Pennsylvania Department of Psychiatry. In addition to his role at EmbarkNeuro, Steve is currently a member of the Board of Directors of Verge Genomics.

Steve received both his PhD in Molecular and Cellular Pharmacology and his MD from the Stony Brook University Renaissance School of Medicine and completed his residency training in the Yale University School of Medicine Department of Psychiatry.